Skip to content

The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment)

The Relationship of Essential Fatty Acids to Cognitive Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01750307
Acronym
OCEAN
Enrollment
80
Registered
2012-12-17
Start date
2012-09-30
Completion date
2015-09-30
Last updated
2012-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Keywords

Attention Deficit Hyperactivity Disorder (ADHD), Essential fatty acids (EFAs), Electroencephalography (EEG), Event-related potential (ERP), Omega 3, Randomised Control Trial, Fish oil, Supplementation, Reading, Spelling, Behaviour, Emotional lability

Brief summary

Brief summary The aim of the study is to provide preliminary data on the relationship of Essential Fatty Acids (EFAs) to cognitive and electrophysiological measures of brain and behavioural functions in adults with attention deficit hyperactivity disorder (ADHD) and controls. This main aim will be achieved in two ways. First the investigators will measure the relationship of the various measures to blood levels of EFAs in ADHD cases and controls. Secondly, the potential effects of dietary supplementation with EFAs on cognitive-electrophysiological and behavioural measures in ADHD cases will be investigated. We will evaluate the extent to which changes in neuronal activity and cognitive performance are related to behavioural and functional measures over time. This is to be carried out by conducting a randomised controlled trial of fish oil supplementation in adults with ADHD (The OCEAN study: Oils and Cognitive Effects in Adult Neurodevelopment). The study design will be a 6-month double blind placebo control study with a group of 80 adults with a diagnosis of ADHD. The group will be divided into 40 participants who receive EFA dietary supplements and 40 who receive placebo, over a 6-month period. Allocation to EFA dietary supplementation and placebo groups will be randomly allocated and blind to both the investigator and participants. In addition a sample of 30 controls will take part in baseline levels of assessment and be used for case-control comparisons to investigate the links between EFA blood levels and cognitive-electrophysiological function at one time point. The study design will enable preliminary data to address the following hypotheses: 1. Changes in cognitive and electrophysiological function (neuronal activity) will be found following supplementation with dietary EFAs. 2. Changes in cognition and/or brain activity will be related to blood levels of EFAs. 3. Changes in cognitive performance and electrophysiological parameters will correlate with behavioural function, affective regulation or functional impairments. 4. At baseline, case-control differences in EFA blood-levels will be found which will be linked to cognitive and electrophysiological function.

Interventions

DIETARY_SUPPLEMENTExperimental fatty acid supplementation

4 x capsules per day. Daily dose: 1584mg EFA

DIETARY_SUPPLEMENTPlacebo comparator: MCT oil softgel

4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill

Sponsors

King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Cases: * Clinical diagnosis of ADHD (combined or inattentive type) * Controls: * Screen below threshold for ADHD

Exclusion criteria

* Cases: * Autism spectrum disorder * Recurrent major depression * Bipolar I disorder * Psychotic disorders * Obsessive compulsive disorder * Learning difficulties (IQ \< 80) * Neurological problems * Drug abuse * Those who are already taking EFA supplements * Metabolic conditions * Infectious diseases * Controls: * ADHD * All other

Design outcomes

Primary

MeasureTime frameDescription
The relationship of essential fatty acids to cognitive and electrophysiological measures of brain and behavioural function6 monthsBrain function will be measured using direct current (DC) electroencephalography (EEG) in participants first while they are at rest and second during 4 cognitive tasks. Behavioural function will be measured through assessment of reading and spelling, emotional lability, ADHD symptoms and other self-ratings of behaviour (such as executive function). These measures will be related to the effect of dietary supplementation and blood levels of EFAs in adults with ADHD.

Secondary

MeasureTime frameDescription
The relationship of essential fatty acids to ADHD0 monthsThis will be assessed by recording blood levels of EFAs in cases and controls at baseline assessment.

Countries

United Kingdom

Contacts

Primary ContactRuth E Cooper
ruth.cooper@kcl.ac.uk+44 207 848 5401
Backup ContactRose Scott
rose.scott@kcl.ac.uk+44 207 848 5712

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026